Pembrolizumab (Keytruda®) as monotherapy for the treatment of microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic colorectal cancer, advanced or recurrent endometrial carcinoma and unresectable or metastatic gastric, small intestine, or biliary cancer. Update July 2022

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) as monotherapy for the treatment of microsatellite instability-high (MSI‑H) or mismatch repair deficient (dMMR) tumours in adults with unresectable or metastatic colorectal cancer, advanced or recurrent endometrial carcinoma and unresectable or metastatic gastric, small intestine, or biliary cancer. Update July 2022. Oncology Fact Sheet Nr. 90.

[thumbnail of Oncology Fact Sheet Nr.90_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
137kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 300-387 Stomach WI Digestive system > WI 400-560 Intestines WI Digestive system > WI 600-650 Anus. Rectum WI Digestive system > WI 700-770 Liver. Billary tract WP Gynaecology > WP 440-468 Uterine diseases
Language:	English
Series Name:	Oncology Fact Sheet Nr. 90
Deposited on:	25 Apr 2022 14:54
Last Modified:	26 Jul 2022 14:48

Repository Staff Only: item control page